Results 121 to 130 of about 2,131 (185)

Reduced Frequency of Prolonged Sporadic Hemiplegic Migraine Attacks Following Fremanezumab Treatment-A Case Report. [PDF]

Eur J Neurol
Hotz JF, Kaindl L, Krebs S, Vigl M, Ferrari J, Neumann C, Han R, Ritscher L, Sykora M, Gallmetzer P.   +9 more
europepmc   +1 more source

Psoriasiform Drug Eruption following Fremanezumab: A Case Report. [PDF]

Case Rep Dermatol
Coffman K, Ross M, Saurborn E, Grimmett A, Cook S.   +4 more
europepmc   +1 more source

A Real-World Study of CGRP Monoclonal Antibodies for Migraine: Long-Term Effectiveness and Treatment Adherence. [PDF]

Eur J Neurol
Suzuki K, Suzuki S, Kobayashi S, Shioda M, Fujita H, Haruyama Y, Hirata K.   +6 more
europepmc   +1 more source

Chronic migraine management with onabotulinumtoxinA and anti-CGRP/R monoclonal antibodies in an Italian real-world setting: update on therapeutic appropriateness and an emerging role of pharmacy. [PDF]

Front Pharmacol
Scuteri D, Naturale MD, Pagliaro M, Brescia A, De Francesco AE, Lawrence GW, Bagetta G, Corasaniti MT.   +7 more
europepmc   +1 more source

Long-term real-world effectiveness and safety of fremanezumab in 1140 patients with migraine and at least 6 months of treatment: third interim analysis of the pan-European PEARL study. [PDF]

Neurol Sci
Ashina M, Mitsikostas DD, Amin FM, Kokturk P, Schankin CJ, Sahin G, Pozo-Rosich P, Dorman PJ, Nežádal T, Poole AC, Martins IP, Sumelahti ML, Ramirez Campos V, Ahn AH, Akcicek H, Tassorelli C.   +15 more
europepmc   +1 more source

Real-world effectiveness and safety of CGRP monoclonal antibodies in elderly migraine patients: a Korean multicenter study. [PDF]

J Headache Pain
Cho S, Kang MK, Moon HS, Lee MJ, Kim SK, Park HK, Ha WS, Chu MK, Gil YE, Kim BS, Cho SJ.   +10 more
europepmc   +1 more source

Effects of Pausing and Re-Initiating Fremanezumab After Continuous 24-Month Treatment for Preventing Difficult-To-Treat Migraine: Prospective, Multicenter, Real-World Data From the GRASP Study Group. [PDF]

Eur J Neurol
Argyriou AA, Dermitzakis EV, Xiromerisiou G, Chondrogianni M, Foska A, Soldatos P, Mavraki E, Rikos D, Litsardopoulos P, Tsivgoulis G, Vikelis M.   +10 more
europepmc   +1 more source

Botulinum Toxin Type A for the Prevention of Migraines: An Umbrella Review of Systematic Reviews. [PDF]

Toxins (Basel)
Chamani G, Jasim H, Minston A, Dias MF, Poluha RL, Gonçalves DAG, Christidis M, Al-Moraissi EA, Christidis N, De la Torre Canales G, Ernberg M.   +10 more
europepmc   +1 more source

Real-world effectiveness of onabotulinumtoxinA as first-line treatment in chronic migraine and sequential transition to anti-CGRP monoclonal antibodies: a retrospective multicenter study. [PDF]

BMC Neurol
Kępczyńska K, Domitrz I, Stępień A, Michalak-Siembida A, Walczak-Ciszewska A.   +4 more
europepmc   +1 more source